Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment
Journal of Personalized Medicine · 10.07.2023 · 13 (7) · 1114
DOI: 10.3390/jpm13071114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 10.07.2023. Verfasst von Sasha Waldstein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pennsylvania Department of Health using Tobacco CURE Funds.
Abstract (Originalsprache)
Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for known mutational differences, tumor side of origin has emerged as an independent prognostic factor, and one that impacts response to therapy. Left- and right-sided colon cancers differ in a number of key ways, including histology, mutational profile, carcinogenesis pathways, and microbiomes. Moreover, the frequency of certain molecular features gradually changes from the ascending colon to rectum. These, as well as features yet to be identified, are likely responsible for the ongoing role of tumor sidedness and colorectal subsites in treatment response and prognosis. Along with tumor molecular profiling, blood-based biopsy enables the identification of targetable mutations and predictive biomarkers of treatment response. With the application of known tumor characteristics including sidedness and subsites as well as the utilization of blood-based biopsy, along with the development of biomarkers and targeted therapies, the field of colorectal cancer continues to evolve towards the personalized management of a heterogeneous cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
- Vancouver Clinic, Vancouver, WA 98664, USA.
- Wellspan Medical Oncology & Hematology, Lebanon, PA 17042, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Cancer Control Program, Penn State Cancer Institute, Hershey, PA 17033, USA.
- Division of Hematology-Oncology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Next-Generation Therapies Program, Penn State Cancer Institute, Hershey, PA 17033, USA.
ORCID-Profile: Nelson S Yee
Förderung
- Pennsylvania Department of Health using Tobacco CURE Funds
Zitieren
APA
Waldstein, S., Spengler, M., Pinchuk, I. V., & Yee, N. S. (2023). Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment. Journal of Personalized Medicine, 13(7), 1114. https://doi.org/10.3390/jpm13071114
Vancouver
Waldstein S, Spengler M, Pinchuk IV, Yee NS. Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment. Journal of Personalized Medicine. 2023;13(7):1114. doi:10.3390/jpm13071114
BibTeX
@article{Waldstein2023,
author = {Waldstein, Sasha and Spengler, Marianne and Pinchuk, Iryna V and Yee, Nelson S},
title = {Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {7},
pages = {1114},
doi = {10.3390/jpm13071114}
}
EUVIMED